Herein, Bhagchandani et al. (16) have incorporated the JAK1/2 inhibitor baricitinib into a combination immunosuppression regimen for eliciting donor-specific allotolerance toward pancreatic islets of Langerhans in a mouse model of T1D (Figure 1). This evidence concerns the gene JAK1 and type 1 diabetes mellitus.